The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Guardant Health Inc’s stock clocked out at $18.19, up 4.84% from its previous closing price of $17.35. In other words, the price has increased by $4.84 from its previous closing price. On the day, 1.35 million shares were traded. GH stock price reached its highest trading level at $18.38 during the session, while it also had its lowest trading level at $17.52.
Ratios:
To gain a deeper understanding of GH’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.24 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 8.53 whereas as Long-Term Debt/Eq ratio is at 8.36.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 18 ’24 when Kalia Kumud bought 2,187 shares for $17.82 per share. The transaction valued at 38,963 led to the insider holds 12,722 shares of the business.
Joyce Meghan V. sold 100 shares of GH for $1,905 on Mar 04 ’24. The Director now owns 4,521 shares after completing the transaction at $19.05 per share. On Dec 04 ’23, another insider, Joyce Meghan V., who serves as the Director of the company, sold 100 shares for $26.34 each. As a result, the insider received 2,634 and left with 4,422 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 2217088256 and an Enterprise Value of 2399084544. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.93 while its Price-to-Book (P/B) ratio in mrq is 13.94. Its current Enterprise Value per Revenue stands at 4.254 whereas that against EBITDA is -5.498.
Stock Price History:
The Beta on a monthly basis for GH is 0.93, which has changed by -0.15158582 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $41.06, while it has fallen to a 52-week low of $15.81. The 50-Day Moving Average of the stock is -3.08%, while the 200-Day Moving Average is calculated to be -31.05%.
Shares Statistics:
It appears that GH traded 1.97M shares on average per day over the past three months and 1663710 shares per day over the past ten days. A total of 121.63M shares are outstanding, with a floating share count of 115.88M. Insiders hold about 4.79% of the company’s shares, while institutions hold 93.80% stake in the company. Shares short for GH as of 1713139200 were 9556452 with a Short Ratio of 4.84, compared to 1710460800 on 7757975. Therefore, it implies a Short% of Shares Outstanding of 9556452 and a Short% of Float of 8.180001.
Earnings Estimates
The stock of Guardant Health Inc (GH) is currently in the spotlight, with 19.0 analysts actively rating and assessing its market standing.On average, analysts expect EPS of -$0.85 for the current quarter, with a high estimate of -$0.66 and a low estimate of -$1.04, while EPS last year was -$1.3. The consensus estimate for the next quarter is -$0.81, with high estimates of -$0.63 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.5 and -$3.81 for the fiscal current year, implying an average EPS of -$3.21. EPS for the following year is -$2.91, with 21.0 analysts recommending between -$1.85 and -$3.48.
Revenue Estimates
In the current quarter, 19 analysts expect revenue to total $150.67M. It ranges from a high estimate of $161.9M to a low estimate of $147.6M. As of the current estimate, Guardant Health Inc’s year-ago sales were $128.71MFor the next quarter, 19 analysts are estimating revenue of $160.9M. There is a high estimate of $166.54M for the next quarter, whereas the lowest estimate is $157.2M.
A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $678M, while the lowest revenue estimate was $658.6M, resulting in an average revenue estimate of $664.02M. In the same quarter a year ago, actual revenue was $563.95MBased on 22 analysts’ estimates, the company’s revenue will be $805.9M in the next fiscal year. The high estimate is $869.9M and the low estimate is $753M.
